For example, loss of CHD1 and ZNF292 occurs at a later stage in ERG-positive tumors than in ERG fusion–negative tumors, but as these lesions are common to both progression pathways, these genes seem to be key drivers of prostate cancer progression. Here, ZNF292 is linked to prostate cancer.